M. Deventer

Development of an Indole-Amide-Based Photoswitchable Cannabinoid Receptor Subtype 1 (CB1R) "Cis-On" Agonist.

C. Sotriffer, M. Decker, M. Lohse, 2022, ACS chemical neuroscience.

NNL-3: A Synthetic Intermediate or a New Class of Hydroxybenzotriazole Esters with Cannabinoid Receptor Activity?

M. Glass, D. Hibbs, I. McGregor, 2021, ACS chemical neuroscience.

Cannabinoid receptor activation potential of the next generation, generic ban evading OXIZID synthetic cannabinoid receptor agonists.

F. Reniero, C. Stove, K. Van Uytfanghe, 2022, Drug testing and analysis.

Off-target activity of NBOMes and NBOMe analogs at the µ opioid receptor

H. Gréen, C. Stove, G. Tocco, 2023, Archives of Toxicology.

Title: Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform

M. Deventer, Annelies Cannaert, Christophe P Stove, 2021 .

Dual-Acting Small Molecules: Subtype-Selective Cannabinoid Receptor 2 Agonist/Butyrylcholinesterase Inhibitor Hybrids Show Neuroprotection in an Alzheimer’s Disease Mouse Model

M. Decker, C. Stove, T. Maurice, 2023, Journal of medicinal chemistry.

Detection in seized samples, analytical characterization, and in vitro metabolism of the newly emerged 5-bromo-indazole-3-carboxamide synthetic cannabinoid receptor agonists.

N. NicDaéid, A. Krotulski, Caitlyn Norman, 2023, Drug testing and analysis.